Even though total Tau measurements in the plasma did not suggest diagnostic potential, the levels of Tau phosphorylated at threonine 181 (plasma pTau181), a novel neuroaxonal damage biomarker, have been reported to successfully separate AD and FTD patients from each other as well as AD patients from healthy controls [38,40,41]. This evidence concerns the gene MAPT and Alzheimer disease.